Ocriplasmin for Vitreoretinal Diseases
Joint Authors
Rahimy, Ehsan
Schwartz, Steven D.
Tsui, Irena
Pan, Carolyn K.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-10-14
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Fibronectin and laminin are clinically relevant plasmin receptors in the eye.
Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication.
A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway.
The results are promising and may impact patient care.
American Psychological Association (APA)
Tsui, Irena& Pan, Carolyn K.& Rahimy, Ehsan& Schwartz, Steven D.. 2012. Ocriplasmin for Vitreoretinal Diseases. BioMed Research International،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-991652
Modern Language Association (MLA)
Tsui, Irena…[et al.]. Ocriplasmin for Vitreoretinal Diseases. BioMed Research International No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-991652
American Medical Association (AMA)
Tsui, Irena& Pan, Carolyn K.& Rahimy, Ehsan& Schwartz, Steven D.. Ocriplasmin for Vitreoretinal Diseases. BioMed Research International. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-991652
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-991652
